Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090714 | 1.00 | ELANE (0.38) | ELANEGPR119USP30RIPK1PDE4A | |
| SCHEMBL7090713 | 1.00 | ELANE (0.38) | ELANEGPR119USP30RIPK1PDE4A | |
| SCHEMBL7092475 | 0.89 | ELANE (0.47) | ELANEGPR119RIPK1KLK7 | |
| SCHEMBL7089023 | 0.89 | ELANE (0.47) | ELANEGPR119RIPK1KLK7 | |
| SCHEMBL6853154 | 0.85 | ELANE (0.37) | ELANEGPR119RIPK1PDE4APDE4B | |
| SCHEMBL6853151 | 0.85 | ELANE (0.37) | ELANEGPR119RIPK1PDE4APDE4B | |
| SCHEMBL6853156 | 0.85 | ELANE (0.37) | ELANEGPR119RIPK1PDE4APDE4B | |
| SCHEMBL3083528 | 0.79 | ELANE (0.49) | ELANEGPR119RIPK1KLK7 | |
| SCHEMBL3083530 | 0.79 | ELANE (0.49) | ELANEGPR119RIPK1KLK7 | |
| SCHEMBL3082464 | 0.79 | ELANE (0.49) | ELANEGPR119RIPK1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6646123-B2 | Antitumor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20030162971-A1 | Pentacyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. | 2003-08-28 | — | — | US | disclosed |
| US-6545151-B2 | Taxol derivative; antitumor agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-08 | — | — | US | disclosed |
| US-20010041796-A1 | Pentacyclic compound | TERASAWA HIROFUMI (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-0826688-B1 | PENTACYCLIC COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6211363-B1 | TAXANE COMPOUNDS; ANTITUMOR AGENTS | DAIICHI PHARAMACEUTICAL CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| US-6075140-A | A TAXOL DERIVATIVE CONTAINING PENTACYCLIC RING IN WHICH 9 AND 10 POSITION HYDROXYL GROUP ARE CHANGED TO CYCLIC ACETAL GROUP IS USEFUL AS ANTITUMOR AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-06-13 | — | — | US | disclosed |
| EP-0826688-A1 | PENTACYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162971-A1 | Pentacyclic compound | RPL31, OXER1, BCOR | ELANE 4110/4885GPR119 1349/4885USP30 1428/4885 |
| US-20010041796-A1 | Pentacyclic compound | RPL31, BCOR, OXER1 | ELANE 4117/4885GPR119 1434/4885USP30 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.